Anti-VEGF (Vascular Endothelial Growth Factor Inhibitor)
Pregnancy: Avoid — anti-VEGF may affect fetal vasculogenesis
Bevacizumab (Intravitreal)
Brand names: Avastin (off-label intravitreal)
Adult dose
Dose: 1.25 mg intravitreal injection monthly for 3 loading doses, then PRN or treat-and-extend.
Route: Intravitreal injection
Frequency: Monthly loading × 3, then PRN
Max: 1.25 mg per intravitreal injection
Off-label for wet AMD (cheaper than ranibizumab). CATT/IVAN trials: non-inferior to ranibizumab for visual acuity. Also used for diabetic macular oedema, CNV, retinal vein occlusion.
Paediatric dose
Route: Intravitreal
Frequency: Monthly
Max: 0.625 mg in ROP (off-label)
Concentration: 25 mg/mL mg/ml
Retinopathy of prematurity (ROP): off-label intravitreal bevacizumab — specialist neonatal/paediatric ophthalmology only
Dose adjustments
Renal
N/A (local injection)
Hepatic
N/A
Clinical pearls
- CATT/IVAN studies: bevacizumab as effective as ranibizumab for visual acuity in wet AMD; approximately 10× cheaper
- Off-label but widely used — prescribe with informed consent documenting off-label status
- Endophthalmitis: most serious complication — patients instructed to report sudden visual loss or eye pain immediately
- Bilateral same-day injection: not recommended (bilateral endophthalmitis risk — single ocular event but bilateral outcome)
Contraindications
- Ocular or periocular infection
- Uncontrolled glaucoma
Side effects
- Endophthalmitis (0.05% — sight-threatening)
- Retinal detachment
- Intraocular haemorrhage
- IOP rise (transient post-injection)
- Arterial thromboembolic events (systemic — theoretical)
Interactions
- None specific for intravitreal route
Monitoring
- Visual acuity before each injection
- OCT imaging (retinal fluid)
- IOP after injection
- Signs of endophthalmitis
Reference: BNFc; BNF; CATT Trial (NEJM 2011); IVAN Trial (Lancet 2013); RCOphth AMD Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Insulin Correction Factor (ICF/ISF) · Insulin Management
- R Factor for Drug-Induced Liver Injury (DILI) · Liver Disease
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme